The European Medicines Agency expects to adopt in October a new approach on how it manages the conflicts of interests of external scientific experts who advise it on the assessment of new drugs and other innovative medicinal products. Vibha Sharma reports from an EMA conference that explored the future sustainability of the current system for authorising and supervising medicines, in London, on 30 June1...
Please login to read the full article.
